

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI499628

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CUREVAC SE	09/03/2024
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	GLAXOSMITHKLINE BIOLOGICALS SA
<b>Street Address:</b>	Rue de l'Institut 89
<b>City:</b>	Rixensart
<b>State/Country:</b>	BELGIUM
<b>Postal Code:</b>	B-1330
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17829004
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	6109176934
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6109175000
<b>Email:</b>	us_cipkop@gsk.com
<b>Correspondent Name:</b>	Liliana Di Nola-Baron
<b>Address Line 1:</b>	1250 South Collegeville Road
<b>Address Line 4:</b>	Collegeville, PENNSYLVANIA 19426
<b>ATTORNEY DOCKET NUMBER:</b>	VB67113US02
<b>NAME OF SUBMITTER:</b>	Sandra Manton
<b>SIGNATURE:</b>	Sandra Manton
<b>DATE SIGNED:</b>	09/17/2024
<b>Total Attachments: 5</b>	
source=Fully executed Confirmatory Assignment CV to GSK#page1.tiff	
source=Fully executed Confirmatory Assignment CV to GSK#page2.tiff	
source=Fully executed Confirmatory Assignment CV to GSK#page3.tiff	
source=Fully executed Confirmatory Assignment CV to GSK#page4.tiff	
source=Fully executed Confirmatory Assignment CV to GSK#page5.tiff	

## CONFIRMATORY ASSIGNMENT

WE, CUREVAC SE, a German corporation with offices at Friedrich-Miescher-Str. 15, 72076 Tübingen, Germany (**hereafter the Assignor**) do hereby declare that in accordance with the JOINT PATENT ASSIGNMENT AND CONTRACT TRANSFER agreement dated 29 June 2024 between the Assignor and GLAXOSMITHKLINE BIOLOGICALS SA, a Belgium corporation with offices at Rue de l'Institut 89, 1330 Rixensart, Belgium (**hereafter the Assignee**), we have at the Effective Date (11 July 2024) assigned to the Assignee all our rights, title and interest in the patents and patent applications listed in the attached Schedule 1, including any and all existing and subsequent divisionals, continuations, continuations-in-part, reissues, extensions, reexaminations and equivalents of any of the foregoing, and any and all existing and subsequent foreign counterparts of any of the foregoing.


This assignment includes any right the Assignor may have to bring action and obtain damages and all other remedies and relief in respect of any infringement of the patents/applications listed in Schedule 1 whether occurring before, on, or after the date of this assignment.

This assignment includes the right (where applicable) to file applications under the Paris Convention, corresponding to or based on any of the applications for the patents and patent applications listed in Schedule 1, and to claim priority from any of the foregoing.

The Assignor has received good and valuable consideration for the assignment, the receipt and sufficiency of which are hereby acknowledged.

Dated this 03.09.2024

Signed for and on behalf of  
CUREVAC SE

  
Authorized Signatory CEO  
CUREVAC SE



CureVac SE  
Friedrich-Miescher-Str. 15  
72076 Tübingen  
Germany  
T: +49 (0) 7071 9883-0  
F: +49 (0) 7071 9883-1101  
www.curevac.com

Signed for and on behalf of  
GLAXOSMITHKLINE BIOLOGICALS SA

\_\_\_\_\_  
Authorized Signatory  
GLAXOSMITHKLINE BIOLOGICALS SA

## CONFIRMATORY ASSIGNMENT

WE, CUREVAC SE, a German corporation with offices at Friedrich-Miescher-Str. 15, 72076 Tübingen, Germany (**hereafter the Assignor**) do hereby declare that in accordance with the JOINT PATENT ASSIGNMENT AND CONTRACT TRANSFER agreement dated 29 June 2024 between the Assignor and GLAXOSMITHKLINE BIOLOGICALS SA, a Belgium corporation with offices at Rue de l'Institut 89, 1330 Rixensart, Belgium (**hereafter the Assignee**), we have at the Effective Date (11 July 2024) assigned to the Assignee all our rights, title and interest in the patents and patent applications listed in the attached Schedule 1, including any and all existing and subsequent divisionals, continuations, continuations-in-part, reissues, extensions, reexaminations and equivalents of any of the foregoing, and any and all existing and subsequent foreign counterparts of any of the foregoing.

This assignment includes any right the Assignor may have to bring action and obtain damages and all other remedies and relief in respect of any infringement of the patents/applications listed in Schedule 1 whether occurring before, on, or after the date of this assignment.

This assignment includes the right (where applicable) to file applications under the Paris Convention, corresponding to or based on any of the applications for the patents and patent applications listed in Schedule 1, and to claim priority from any of the foregoing.


The Assignor has received good and valuable consideration for the assignment, the receipt and sufficiency of which are hereby acknowledged.

Dated this 9 Sept 2024

Signed for and on behalf of  
CUREVAC SE

\_\_\_\_\_  
Authorized Signatory  
CUREVAC SE

Signed for and on behalf of  
GLAXOSMITHKLINE BIOLOGICALS SA

  
Sophie C. Racine  
Authorized Signatory  
GLAXOSMITHKLINE BIOLOGICALS SA

**SCHEDULE 1**

Reference	Country	Patent Status	Filing Date	Application Number	Grant Date	Patent Number
<b>70259 FAMILY - NUCLEIC ACID BASED VACCINE</b>						
70259DE01	Germany	Granted	26-Oct-23	202023106198.2	21-Mar-24	202023106198
70259GB01P	United Kingdom	Lapsed	28-Oct-22	2216023.8	N\A	N/A
70259GB02P	United Kingdom	Lapsed	23-Jan-23	2300950.9	N\A	N/A
70259GB03P	United Kingdom	Lapsed	30-May-23	2308048.4	N\A	N/A
70259GB04P	United Kingdom	Lapsed	04-Aug-23	2311985.2	N\A	N/A
70259US01T	United States of America	Published	26-Oct-23	18/494893	N\A	N/A
70259WO01	PCT	Published	26-Oct-23	PCT/IB2023/060807	N\A	N/A
<b>70418 FAMILY - NUCLEIC ACID BASED VACCINE'</b>						
70418GB01P	United Kingdom	Application	18-Oct-23	2315944.5	N\A	N/A
70418GB02P	United Kingdom	Application	07-Dec-23	2318721.4	N\A	N/A
<b>VB67113 FAMILY - RNA VACCINE AGAINST SARS-COV-2 VARIANTS</b>						
VB67113AU01	Australia	Application	21-Dec-21	2021405281	N\A	N/A
VB67113BR01	Brazil	Published	21-Dec-21	BR112023012303-8	N\A	N/A
VB67113CA01	Canada	Application	21-Dec-21	3205569	N\A	N/A
VB67113CN01	China	Published	21-Dec-21	202180092578.2	N\A	N/A
VB67113EA01	Eurasian Patent Convention	Application	21-Dec-21	202391493	N\A	N/A
VB67113EP01	European Patent	Published	21-Dec-21	21836244.0	N\A	N/A
VB67113HK01	Hong Kong	Application	22-Dec-21	62024089776.4	N\A	N/A
VB67113IL01	Israel	Application	21-Dec-21	303976	N\A	N/A
VB67113IN01	India	Published	21-Dec-21	202317046570	N\A	N/A
VB67113JP01	Japan	Application	21-Dec-21	2023-561934	N\A	N/A
VB67113KR01	South Korea	Application	21-Dec-21	10-2023-7024723	N\A	N/A
VB67113MX01	Mexico	Published	21-Dec-21	MX/a/2023/007574	N\A	N/A

VB67113SG01	Singapore	Application	21-Dec-21	11202304550S	N\A	N/A
VB67113US01	United States of America	Granted	21-Dec-21	17/558257	05-Mar-24	11918643
VB67113US02	United States of America	Granted	31-May-22	17/829004	16-Jan-24	11872280
VB67113US03	United States of America	Published	21-Dec-21	18/268736	N\A	N/A
VB67113WO04	PCT	Lapsed	21-Dec-21	PCT/IB2021/062127	N\A	N/A
VB67113ZA01	South Africa	Application	21-Dec-21	2023/06448	N\A	N/A
<b>70210 FAMILY - INFLUENZA VIRUS VACCINES</b>						
70210US01P	United States of America	Lapsed	26-Sep-22	63/409895	N\A	N/A
70210US02P	United States of America	Lapsed	27-Apr-23	63/498544	N\A	N/A
70210WO01	PCT	Published	25-Sep-23	PCT/EP2023/076393	N\A	N/A
<b>70307 FAMILY - INFLUENZA VIRUS VACCINES</b>						
70307GB01P	United Kingdom	Lapsed	27-Apr-23	2306220.1	N\A	N/A
70307GB02P	United Kingdom	Application	25-Sep-23	2314629.3	N\A	N/A
70307WO01	PCT	Application	25-Apr-24	PCT/EP2024/061356	N\A	N/A
<b>70331 FAMILY - INFLUENZA VIRUS VACCINES</b>						
70331US01P	United States of America	Lapsed	27-Apr-23	63/498550	N\A	N/A
70331US02P	United States of America	Application	25-Sep-23	63/584940	N\A	N/A
70331WO01	PCT	Application	25-Apr-24	PCT/EP2024/061349	N\A	N/A
<b>70448 FAMILY - INFLUENZA VIRUS VACCINES</b>						
70448US01P	United States of America	Application	21-Dec-23	63/613286	N\A	N/A
<b>VB66985 FAMILY - IMMUNOGENIC COMPOSITIONS</b>						
VB66985BR02	Brazil	Application	25-Mar-22	BR112023019078-9	N\A	N/A
VB66985CA02	Canada	Application	25-Mar-22	3212653	N\A	N/A

VB66985CN02	China	Published	25-Mar-22	202280024333.0	N\A	N/A
VB66985EP02	European Patent	Published	25-Mar-22	22719224.2	N\A	N/A
VB66985HK02	Hong Kong	Published	25-Mar-22	62024087245.2	N\A	N/A
VB66985IN02	India	Application	25-Mar-22	202317062603	N\A	N/A
VB66985JP02	Japan	Application	25-Mar-22	2023-559678	N\A	N/A
VB66985MX02	Mexico	Published	25-Mar-22	MX/a/2023/011400	N\A	N/A
VB66985US02	United States of America	Published	25-Mar-22	18/283601	N\A	N/A
VB66985WO02	PCT	Lapsed	25-Mar-22	PCT/EP2022/057934	N\A	N/A